Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
|---|---|---|---|---|---|---|
| Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Received | |||
| TBC | zolbetuximab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Pending | |||
| TBC | momelotinib | Myelofibrosis | Pending | |||
| Awiqli | insulin icodec | Diabetes mellitus, type 2 | Active | |||
| TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Suspended | |||
| Qulipta | atogepant | Migraine, prevention | Active | |||
| Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Active | |||
| Vraylar | cariprazine | Schizophrenia | Active | |||
| Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Received | |||
| Oncaspar | pegaspargase | Adult Acute Lymphocytic Leukemia (ALL) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed |
Last Updated : May 16, 2024